{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:42:18Z","timestamp":1777030938571,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T00:00:00Z","timestamp":1486425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/bjc.2017.22","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T21:02:21Z","timestamp":1486501341000},"page":"731-741","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Prognostication and monitoring of mesothelioma using biomarkers: a systematic review"],"prefix":"10.1038","volume":"116","author":[{"given":"David T","family":"Arnold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duneesha","family":"De Fonseka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fergus W","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najib M","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick A","family":"Maskell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,7]]},"reference":[{"issue":"2","key":"BFbjc201722_CR1","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/0300060513504163","volume":"42","author":"O Abakay","year":"2014","unstructured":"Abakay O, Tanrikulu AC, Palanci Y, Abakay A (2014) The value of inflammatory parameters in the prognosis of malignant mesothelioma. J Int Med Res 42 (2): 554\u2013565.","journal-title":"J Int Med Res"},{"issue":"7306","key":"BFbjc201722_CR2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/bmj.323.7306.224","volume":"323","author":"DG Altman","year":"2001","unstructured":"Altman DG (2001) Systematic reviews of evaluations of prognostic variables. BMJ 323 (7306): 224\u2013228.","journal-title":"BMJ"},{"issue":"5","key":"BFbjc201722_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1373\/clinchem.2008.117465","volume":"55","author":"PH Anborgh","year":"2009","unstructured":"Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF (2009) New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem 55 (5): 895\u2013903.","journal-title":"Clin Chem"},{"issue":"4","key":"BFbjc201722_CR4","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.2214\/AJR.05.0076","volume":"186","author":"SG Armato 3rd","year":"2006","unstructured":"Armato SG 3rd, Ogarek JL, Starkey A, Vogelzang NJ, Kindler HL, Kocherginsky M, MacMahon H (2006) Variability in mesothelioma tumor response classification. AJR Am J Roentgenol 186 (4): 1000\u20131006.","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"BFbjc201722_CR5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/bjc.2015.77","volume":"112","author":"DT Arnold","year":"2015","unstructured":"Arnold DT, Hooper CE, Morley A, White P, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Rahman NM, De Winton E, Clive A, Masani V, Dangoor A, Guglani S, Jankowska P, Lowndes SA, Harvey JE, Braybrooke JP, Maskell NA (2015) The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial. Br J Cancer 112 (7): 1183\u20131189.","journal-title":"Br J Cancer"},{"issue":"4B","key":"BFbjc201722_CR6","first-page":"2971","volume":"17","author":"JM Bonfrer","year":"1997","unstructured":"Bonfrer JM, Schouwink JH, Korse CM, Baas P (1997) Cyfra 21-1 and TPA as markers in malignant mesothelioma. Anticancer Res 17 (4B): 2971\u20132973.","journal-title":"Anticancer Res"},{"issue":"5","key":"BFbjc201722_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/thx.2007.081430","volume":"63","author":"A Chapman","year":"2008","unstructured":"Chapman A, Mulrennan S, Ladd B, Muers MF (2008) Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 63 (5): 435\u2013439.","journal-title":"Thorax"},{"issue":"10","key":"BFbjc201722_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","volume":"69","author":"J Creaney","year":"2014","unstructured":"Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YC, Skates SJ, Nowak AK, Robinson BW (2014) Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 69 (10): 895\u2013902.","journal-title":"Thorax"},{"issue":"3","key":"BFbjc201722_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","volume":"82","author":"J Creaney","year":"2013","unstructured":"Creaney J, Dick IM, Segal A, Musk AW, Robinson BW (2013) Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer 82 (3): 491\u2013498.","journal-title":"Lung Cancer"},{"issue":"5","key":"BFbjc201722_CR10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","volume":"17","author":"J Creaney","year":"2011","unstructured":"Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK (2011) Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res 17 (5): 1181\u20131189.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"BFbjc201722_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/thx.2006.068114","volume":"62","author":"J Creaney","year":"2007","unstructured":"Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW (2007) Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 62 (7): 569\u2013576.","journal-title":"Thorax"},{"issue":"17","key":"BFbjc201722_CR12","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","volume":"13","author":"A Cristaudo","year":"2007","unstructured":"Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R (2007) Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 13 (17): 5076\u20135081.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"BFbjc201722_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/1097-0142(19890701)64:1<68::AID-CNCR2820640112>3.0.CO;2-I","volume":"64","author":"IM Dahl","year":"1989","unstructured":"Dahl IM, Solheim OP, Erikstein B, Muller E (1989) A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease. Cancer 64 (1): 68\u201373.","journal-title":"Cancer"},{"key":"BFbjc201722_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/2046-4053-3-140","volume":"3","author":"J Dretzke","year":"2014","unstructured":"Dretzke J, Ensor J, Bayliss S, Hodgkinson J, Lordkipanidze M, Riley RD, Fitzmaurice D, Moore D (2014) Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease. Syst Rev 3: 140.","journal-title":"Syst Rev"},{"issue":"5","key":"BFbjc201722_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000087376","volume":"26","author":"R Filiberti","year":"2005","unstructured":"Filiberti R, Marroni P, Neri M, Ardizzoni A, Betta PG, Cafferata MA, Canessa PA, Puntoni R, Ivaldi GP, Paganuzzi M (2005) Serum PDGF-AB in pleural mesothelioma. Tumour Biol 26 (5): 221\u2013226.","journal-title":"Tumour Biol"},{"issue":"2","key":"BFbjc201722_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1155\/2012\/430689","volume":"32","author":"A Franko","year":"2012","unstructured":"Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M (2012) Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. Dis Markers 32 (2): 123\u2013131.","journal-title":"Dis Markers"},{"issue":"12","key":"BFbjc201722_CR17","doi-asserted-by":"publisher","first-page":"e115647","DOI":"10.1371\/journal.pone.0115647","volume":"9","author":"N Fujimoto","year":"2014","unstructured":"Fujimoto N, Ohnuma K, Aoe K, Hosono O, Yamada T, Kishimoto T, Morimoto C (2014) Clinical significance of soluble CD26 in malignant pleural mesothelioma. PLoS ONE 9 (12): e115647.","journal-title":"PLoS ONE"},{"issue":"4","key":"BFbjc201722_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/bjc.2013.815","volume":"110","author":"B Ghanim","year":"2014","unstructured":"Ghanim B, Hoda MA, Klikovits T, Winter MP, Alimohammadi A, Grusch M, Dome B, Arns M, Schenk P, Jakopovic M, Samarzija M, Brcic L, Filipits M, Laszlo V, Klepetko W, Berger W, Hegedus B (2014) Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma. Br J Cancer 110 (4): 984\u2013990.","journal-title":"Br J Cancer"},{"issue":"2","key":"BFbjc201722_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/SLA.0b013e3182602af4","volume":"256","author":"B Ghanim","year":"2012","unstructured":"Ghanim B, Hoda MA, Winter MP, Klikovits T, Alimohammadi A, Hegedus B, Dome B, Grusch M, Arns M, Schenk P, Pohl W, Zielinski C, Filipits M, Klepetko W, Berger W (2012) Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. Ann Surg 256 (2): 357\u2013362.","journal-title":"Ann Surg"},{"issue":"10","key":"BFbjc201722_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","volume":"179","author":"BD Grigoriu","year":"2009","unstructured":"Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A (2009) Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 179 (10): 950\u2013954.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"BFbjc201722_CR21","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","volume":"13","author":"BD Grigoriu","year":"2007","unstructured":"Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13 (10): 2928\u20132935.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"BFbjc201722_CR22","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/cncr.28875","volume":"120","author":"R Hassan","year":"2014","unstructured":"Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I (2014) Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120 (21): 3311\u20133319.","journal-title":"Cancer"},{"issue":"4","key":"BFbjc201722_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","volume":"158","author":"JA Hayden","year":"2013","unstructured":"Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C (2013) Assessing bias in studies of prognostic factors. Ann Intern Med 158 (4): 280\u2013286.","journal-title":"Ann Intern Med"},{"issue":"1B","key":"BFbjc201722_CR24","first-page":"531","volume":"23","author":"M Hedman","year":"2003","unstructured":"Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O (2003) Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res 23 (1B): 531\u2013536.","journal-title":"Anticancer Res"},{"issue":"1","key":"BFbjc201722_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.rmed.2010.10.010","volume":"105","author":"N Hirayama","year":"2011","unstructured":"Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, Fukuoka K, Nakano T (2011) Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma. Respir Med 105 (1): 137\u2013142.","journal-title":"Respir Med"},{"issue":"11","key":"BFbjc201722_CR26","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","volume":"6","author":"K Hollevoet","year":"2011","unstructured":"Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P, Germonpre P, Kellen E, Legrand C, Kishi Y, Delanghe JR, van Meerbeeck JP (2011) Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol 6 (11): 1930\u20131937.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"BFbjc201722_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1378\/chest.11-0129","volume":"141","author":"K Hollevoet","year":"2012","unstructured":"Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpre P, De Vuyst P, Bosquee L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP (2012) The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. Chest 141 (2): 477\u2013484.","journal-title":"Chest"},{"issue":"6","key":"BFbjc201722_CR28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","volume":"181","author":"K Hollevoet","year":"2010","unstructured":"Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP (2010) Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 181 (6): 620\u2013625.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"BFbjc201722_CR29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/bjc.2015.62","volume":"112","author":"CE Hooper","year":"2015","unstructured":"Hooper CE, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Morley A, White P, Rahman NM, De Winton E, Clive A, Masani V, Arnold DT, Dangoor A, Guglani S, Jankowska P, Lowndes SA, Harvey JE, Braybrooke JP, Maskell NA (2015) The south west area mesothelioma and pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication. Br J Cancer 112 (7): 1175\u20131182.","journal-title":"Br J Cancer"},{"issue":"2","key":"BFbjc201722_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.lungcan.2011.06.007","volume":"75","author":"SC Kao","year":"2012","unstructured":"Kao SC, Harvie R, Paturi F, Taylor R, Davey R, Abraham R, Clarke S, Marx G, Cullen M, Kerestes Z, Pavlakis N (2012) The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin\/gemcitabine. Lung Cancer 75 (2): 248\u2013254.","journal-title":"Lung Cancer"},{"issue":"4","key":"BFbjc201722_CR31","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.7314\/APJCP.2015.16.4.1403","volume":"16","author":"H Kaya","year":"2015","unstructured":"Kaya H, Demir M, Taylan M, Sezgi C, Tanrikulu AC, Yilmaz S, Bayram M, Kaplan I, Senyigit A (2015) Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma. Asian Pac J Cancer Prev 16 (4): 1403\u20131407.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"20","key":"BFbjc201722_CR32","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30 (20): 2509\u20132515.","journal-title":"J Clin Oncol"},{"issue":"6","key":"BFbjc201722_CR33","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/bjc.2015.286","volume":"113","author":"MB Kirschner","year":"2015","unstructured":"Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, Edelman JJ, Kao SC, Hyland R, Dong Y, Laszlo V, Klikovits T, Vallely MP, Grusch M, Hegedus B, Dome B, Klepetko W, van Zandwijk N, Klebe S, Reid G (2015) Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer 113 (6): 963\u2013969.","journal-title":"Br J Cancer"},{"key":"BFbjc201722_CR34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/1471-2407-14-674","volume":"14","author":"M Linch","year":"2014","unstructured":"Linch M, Gennatas S, Kazikin S, Iqbal J, Gunapala R, Priest K, Severn J, Norton A, Ayite B, Bhosle J, O\u2019Brien M, Popat S (2014) A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer 14: 674.","journal-title":"BMC Cancer"},{"issue":"2","key":"BFbjc201722_CR35","first-page":"145","volume":"5","author":"T Mori","year":"2013","unstructured":"Mori T, Tajima K, Hirama M, Sato T, Kido K, Iwakami S, Sasaki S, Iwase A, Shiomi K, Maeda M, Hino O, Takahashi K (2013) The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. J Thorac Dis 5 (2): 145\u2013148.","journal-title":"J Thorac Dis"},{"key":"BFbjc201722_CR36","doi-asserted-by":"publisher","first-page":"419853","DOI":"10.1155\/2014\/419853","volume":"2014","author":"F Mundt","year":"2014","unstructured":"Mundt F, Heidari-Hamedani G, Nilsonne G, Metintas M, Hjerpe A, Dobra K (2014a) Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Biomed Res Int 2014: 419853.","journal-title":"Biomed Res Int"},{"issue":"3","key":"BFbjc201722_CR37","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1074\/mcp.M113.030775","volume":"13","author":"F Mundt","year":"2014","unstructured":"Mundt F, Johansson HJ, Forshed J, Arslan S, Metintas M, Dobra K, Lehtio J, Hjerpe A (2014b) Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma. Mol Cell Proteomics 13 (3): 701\u2013715.","journal-title":"Mol Cell Proteomics"},{"issue":"6","key":"BFbjc201722_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/bjc.1998.150","volume":"77","author":"T Nakano","year":"1998","unstructured":"Nakano T, Chahinian AP, Shinjo M, Tonomura A, Miyake M, Togawa N, Ninomiya K, Higashino K (1998) Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 77 (6): 907\u2013912.","journal-title":"Br J Cancer"},{"issue":"3","key":"BFbjc201722_CR39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","volume":"81","author":"AK Nowak","year":"2013","unstructured":"Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PL, Pavlakis N, Boyer M, Stockler MR (2013) A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer 81 (3): 422\u2013427.","journal-title":"Lung Cancer"},{"issue":"6","key":"BFbjc201722_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jtho.2016.02.006","volume":"11","author":"HI Pass","year":"2016","unstructured":"Pass HI, Goparaju C, Espin-Garcia O, Donington J, Carbone M, Patel D, Chen Z, Feld R, Cho J, Gadgeel S, Wozniak A, Chachoua A, Leighl N, Tsao MS, de Perrot M, Xu W, Liu G (2016) Plasma biomarker enrichment of clinical prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 11 (6): 900\u2013909.","journal-title":"J Thorac Oncol"},{"issue":"15","key":"BFbjc201722_CR41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","volume":"367","author":"HI Pass","year":"2012","unstructured":"Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367 (15): 1417\u20131427.","journal-title":"N Engl J Med"},{"issue":"15","key":"BFbjc201722_CR42","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMoa051185","volume":"353","author":"HI Pass","year":"2005","unstructured":"Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353 (15): 1564\u20131573.","journal-title":"N Engl J Med"},{"issue":"1","key":"BFbjc201722_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","volume":"85","author":"HI Pass","year":"2008","unstructured":"Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J (2008) Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85 (1): 265\u2013272.","journal-title":"Ann Thorac Surg"},{"issue":"2","key":"BFbjc201722_CR44","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3233\/CBM-140448","volume":"15","author":"J Raphael","year":"2015","unstructured":"Raphael J, Massard C, Gong IY, Farace F, Margery J, Billiot F, Hollebecque A, Besse B, Soria JC, Planchard D (2015) Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma. Cancer Biomark 15 (2): 151\u2013156.","journal-title":"Cancer Biomark"},{"issue":"9396","key":"BFbjc201722_CR45","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","volume":"362","author":"BW Robinson","year":"2003","unstructured":"Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362 (9396): 1612\u20131616.","journal-title":"Lancet"},{"issue":"11","key":"BFbjc201722_CR46","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","volume":"3","author":"J Schneider","year":"2008","unstructured":"Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T (2008) Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 3 (11): 1317\u20131324.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"BFbjc201722_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0169-5002(99)00044-6","volume":"25","author":"H Schouwink","year":"1999","unstructured":"Schouwink H, Korse CM, Bonfrer JM, Hart AA, Baas P (1999) Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 25 (1): 25\u201332.","journal-title":"Lung Cancer"},{"key":"BFbjc201722_CR48","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1756-9966-31-26","volume":"31","author":"F Shojaei","year":"2012","unstructured":"Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E (2012) Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res 31: 26.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"BFbjc201722_CR49","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.824","volume":"193","author":"L Strizzi","year":"2001","unstructured":"Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G, Puntoni R, Mutti L, Procopio A (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193 (4): 468\u2013475.","journal-title":"J Pathol"},{"key":"BFbjc201722_CR50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1471-2407-13-205","volume":"13","author":"C Tabata","year":"2013","unstructured":"Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, Masachika E, Nishizaki T, Nakano T (2013) Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 13: 205.","journal-title":"BMC Cancer"},{"issue":"6B","key":"BFbjc201722_CR51","first-page":"3933","volume":"28","author":"K Tajima","year":"2008","unstructured":"Tajima K, Hirama M, Shiomi K, Ishiwata T, Yoshioka M, Iwase A, Iwakami S, Yamazaki M, Toba M, Tobino K, Sugano K, Ichikawa M, Hagiwara Y, Takahashi K, Hino O (2008) ERC\/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. Anticancer Res 28 (6B): 3933\u20133936.","journal-title":"Anticancer Res"},{"issue":"5","key":"BFbjc201722_CR52","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U","volume":"92","author":"A Thylen","year":"2001","unstructured":"Thylen A, Hjerpe A, Martensson G (2001) Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 92 (5): 1224\u20131230.","journal-title":"Cancer"},{"issue":"10","key":"BFbjc201722_CR53","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.0.CO;2-N","volume":"86","author":"A Thylen","year":"1999","unstructured":"Thylen A, Wallin J, Martensson G (1999) Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma. Cancer 86 (10): 2000\u20132005.","journal-title":"Cancer"},{"issue":"14","key":"BFbjc201722_CR54","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin vs cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (14): 2636\u20132644.","journal-title":"J Clin Oncol"},{"issue":"20","key":"BFbjc201722_CR55","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","volume":"28","author":"P Wheatley-Price","year":"2010","unstructured":"Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O\u2019Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G (2010) Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma. J Clin Oncol 28 (20): 3316\u20133322.","journal-title":"J Clin Oncol"},{"issue":"10","key":"BFbjc201722_CR56","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1515\/CCLM.2011.242","volume":"49","author":"S Yamada","year":"2011","unstructured":"Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T (2011) Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 49 (10): 1721\u20131726.","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"BFbjc201722_CR57","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","volume":"5","author":"A Yasumitsu","year":"2010","unstructured":"Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T (2010) Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol 5 (4): 479\u2013483.","journal-title":"J Thorac Oncol"},{"issue":"10026","key":"BFbjc201722_CR58","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Riviere F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A French Cooperative Thoracic I (2016) Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387 (10026): 1405\u20131414.","journal-title":"Lancet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201722","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:38:35Z","timestamp":1684417115000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,7]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFbjc201722"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.22","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,7]]},"assertion":[{"value":"18 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}